Hepatic Infantile Hemangiomas Treated with Oral Propranolol—A Case Series

Abstract:  Hepatic infantile hemangiomas may be associated with morbidity and mortality, and traditional therapies may be associated with significant side effects. Since propranolol has been recently used successfully to treat cutaneous infantile hemangiomas, we decided to use it in three patients who presented with hepatic and skin hemangiomatosis. Three patients with skin and hepatic infantile hemangiomas, two of whom had evidence of cardiovascular compromise and one of whom had extensive liver involvement and hypothyroidism, were treated with oral propranolol. Regression of both skin and hepatic hemangiomas was noted in all patients, as was resolution of the cardiac symptoms and decreased thyroid requirement in two patients each. Propranolol was well tolerated without any adverse effects. Propranolol should be considered as a potential first‐line therapy in patients with symptomatic hepatic hemangiomatosis.

[1]  Z. N. D. de Oliveira,et al.  Propranolol for treatment of infantile hemangiomas* , 2013, Anais brasileiros de dermatologia.

[2]  C. Bodemer,et al.  Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. , 2010, The Journal of pediatrics.

[3]  R. Alaggio,et al.  Massive response of severe infantile hepatic hemangioma to propanolol , 2010, Pediatric blood & cancer.

[4]  E. Morii,et al.  Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism , 2010, European Journal of Pediatrics.

[5]  C. Ceran,et al.  Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report. , 2009, Journal of pediatric hematology/oncology.

[6]  B. Dembowska-Baginska,et al.  Hemodynamic failure as an indication to urgent liver transplantation in infants with giant hepatic hemangiomas or vascular malformations – Report of four cases , 2009, Pediatric transplantation.

[7]  U. Dyamenahalli,et al.  Propranolol for airway hemangiomas: Case report of novel treatment , 2009, The Laryngoscope.

[8]  D. Lipsker,et al.  Propranolol for Severe Infantile Hemangiomas: Follow-Up Report , 2009, Pediatrics.

[9]  J. L. Todd,et al.  Propranolol Treatment for Hemangioma of Infancy: Risks and Recommendations , 2009, Pediatric dermatology.

[10]  Yukio Yoneda,et al.  Functional expression of β2 adrenergic receptors responsible for protection against oxidative stress through promotion of glutathione synthesis after Nrf2 upregulation in undifferentiated mesenchymal C3H10T1/2 stem cells , 2009, Journal of cellular physiology.

[11]  R. Azizkhan,et al.  Spectrum of hepatic hemangiomas: management and outcome. , 2009, Journal of pediatric surgery.

[12]  Anne W. Lucky,et al.  Growth Characteristics of Infantile Hemangiomas: Implications for Management , 2008, Pediatrics.

[13]  F. Boralevi,et al.  Propranolol for severe hemangiomas of infancy. , 2008, The New England journal of medicine.

[14]  N. Howard,et al.  Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas , 2008, Current opinion in pediatrics.

[15]  R. Kalpatthi,et al.  Thyroid abnormalities in infantile hepatic hemangioendothelioma , 2007, Pediatric blood & cancer.

[16]  J. Mulliken,et al.  Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. , 2007, Journal of pediatric surgery.

[17]  G. Bennett,et al.  Paclitaxel- and vincristine-evoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cells , 2006, Experimental Neurology.

[18]  N. Sikka,et al.  Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. , 2004, The Journal of emergency medicine.

[19]  D. Zurakowski,et al.  Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy. , 2004, AJR. American journal of roentgenology.

[20]  A. Clerico,et al.  Recombinant Interferon Alfa 2A in Hepatic Hemangiomatosis with Congestive Heart Failure: A Case Report , 2003, Pediatric hematology and oncology.

[21]  S. Ko,et al.  Infantile hepatic hemangioendothelioma presenting as early heart failure: report of two cases. , 2002, Chang Gung medical journal.

[22]  S. K. Sommers Smith,et al.  Beta blockade induces apoptosis in cultured capillary endothelial cells , 2002, In Vitro Cellular & Developmental Biology - Animal.

[23]  S. Hurvitz,et al.  Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. , 2000, Journal of pediatric hematology/oncology.

[24]  D. Metry,et al.  Benign cutaneous vascular tumors of infancy: when to worry, what to do. , 2000, Archives of dermatology.

[25]  J. Mulliken,et al.  Complications of systemic corticosteroid therapy for problematic hemangioma. , 1999, Plastic and reconstructive surgery.

[26]  J. Mulliken,et al.  Spastic Diplegia as a Complication of Interferon Alfa‐2a Treatment of Hemangiomas of Infancy , 1998, The Journal of pediatrics.

[27]  J. Mulliken,et al.  Hepatic vascular anomalies in infancy: a twenty-seven-year experience. , 1996, The Journal of pediatrics.

[28]  N. Swanson,et al.  Multimodal management of diffuse neonatal hemangiomatosis. , 1996, Journal of the American Academy of Dermatology.

[29]  R. Leithiser,et al.  Infantile hepatic hemangioma: Doppler US. , 1992, Radiology.

[30]  M. Riché,et al.  Management of alarming hemangiomas in infancy: a review of 25 cases. , 1990, Pediatrics.

[31]  G. Mahour,et al.  Management of massive hepatic hemangiomas in infants and children: a review of 13 cases. , 1982, Pediatrics.

[32]  A. H. Jacobs.  Strawberry hemangiomas; the natural history of the untreated lesion. , 1957, California medicine.